Autolus Pretax Profit Margin from 2010 to 2024
| AUTL Stock | USD 4.56 0.04 0.88% |
Pretax Profit Margin | First Reported 2010-12-31 | Previous Quarter (122.73) | Current Value (128.87) | Quarterly Volatility 171.47860743 |
Check Autolus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Autolus main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 7.2 M or Total Revenue of 281.2 K, as well as many exotic indicators such as Price To Sales Ratio of 436, Dividend Yield of 0.0 or PTB Ratio of 10.55. Autolus financial statements analysis is a perfect complement when working with Autolus Therapeutics Valuation or Volatility modules.
Autolus | Pretax Profit Margin |
Latest Autolus Therapeutics' Pretax Profit Margin Growth Pattern
Below is the plot of the Pretax Profit Margin of Autolus Therapeutics over the last few years. It is Autolus Therapeutics' Pretax Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Autolus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Pretax Profit Margin | 10 Years Trend |
|
Pretax Profit Margin |
| Timeline |
Autolus Pretax Profit Margin Regression Statistics
| Arithmetic Mean | (83.53) | |
| Coefficient Of Variation | (205.30) | |
| Mean Deviation | 91.74 | |
| Median | (27.96) | |
| Standard Deviation | 171.48 | |
| Sample Variance | 29,405 | |
| Range | 675 | |
| R-Value | (0.37) | |
| Mean Square Error | 27,413 | |
| R-Squared | 0.13 | |
| Significance | 0.18 | |
| Slope | (14.05) | |
| Total Sum of Squares | 411,669 |
Autolus Pretax Profit Margin History
About Autolus Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Autolus Therapeutics income statement, its balance sheet, and the statement of cash flows. Autolus Therapeutics investors use historical funamental indicators, such as Autolus Therapeutics's Pretax Profit Margin, to determine how well the company is positioned to perform in the future. Although Autolus Therapeutics investors may use each financial statement separately, they are all related. The changes in Autolus Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Autolus Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Autolus Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Autolus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (122.73) | (128.87) |
Pair Trading with Autolus Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Autolus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Autolus Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Autolus Stock
| 0.63 | ELYM | Eliem Therapeutics | PairCorr |
| 0.42 | PAHC | Phibro Animal Health Financial Report 1st of May 2024 | PairCorr |
| 0.42 | ANIP | ANI Pharmaceuticals Financial Report 13th of May 2024 | PairCorr |
The ability to find closely correlated positions to Autolus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Autolus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Autolus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Autolus Therapeutics to buy it.
The correlation of Autolus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Autolus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Autolus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Autolus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Autolus Therapeutics Correlation against competitors. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Autolus Stock analysis
When running Autolus Therapeutics' price analysis, check to measure Autolus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Autolus Therapeutics is operating at the current time. Most of Autolus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Autolus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Autolus Therapeutics' price. Additionally, you may evaluate how the addition of Autolus Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is Autolus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.20) | Revenue Per Share 0.01 | Quarterly Revenue Growth (1.00) | Return On Assets (0.25) | Return On Equity (1.02) |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.